Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Xeris Biopharma Holdings Effective Interest Rate on Debt % Related Terms
Xeris Biopharma Holdings Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Xeris Biopharma Holdings's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings Effective Interest Rate on Debt % Chart
FRA:2B30 vs HROW, PRGO, PAHC: Effective Interest Rate on Debt % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Effective Interest Rate on Debt % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 10.73% mean?
Xeris Biopharma Holdings (FRA:2B30) has a Effective Interest Rate on Debt % of 10.73% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Xeris Biopharma Holdings and its competitors.
Is Xeris Biopharma Holdings' Effective Interest Rate on Debt % too high?
Xeris Biopharma Holdings' current Effective Interest Rate on Debt % is 10.73%. Overall, Xeris Biopharma Holdings has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Effective Interest Rate on Debt % compare to HROW and PRGO?
Xeris Biopharma Holdings' Effective Interest Rate on Debt % of 10.73% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Drug Manufacturers company?
A good Effective Interest Rate on Debt % depends on the Drug Manufacturers industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Effective Interest Rate on Debt % is 10.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.48, compared to a current price of €6.89 — trading 53.8% above its estimated fair value. The current Effective Interest Rate on Debt % is 10.73%. Xeris Biopharma Holdings' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current Effective Interest Rate on Debt % is 10.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €6.89 is trading 53.8% above its estimated GF Value™ of €4.48.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for FRA:2B30:
Effective Interest Rate on Debt %: 10.73%
GF Value™: €4.48 vs. price of €6.89 (53.8% above fair value)
No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score
Get the complete analysis for FRA:2B30
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2B30 has been successfully added to your 
